Concepedia
Institution (Healthcare)
Kyiv City Clinical Oncology Center
Also Known As
Kyiv City Clinical Oncology Center · Acronym: KCCOC
2.9K
Publications
54.1K
Citations
161
Authors
538
Concepts
Home
1
26
150
4.1K
2
19
28
3.5K
3
79
4
72
5
15
×
All Concepts
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn, John Crown, István Láng, +15
The Lancet Oncology
Cyclin-dependent Kinase 4/6Breast OncologyInhibitor PalbociclibMedicinePharmacology +9
2014
1.9K
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Maha Hussain, Karim Fizazi, Fred Saad, +9
New England Journal of Medicine
2018
1K
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki, +16
Hematological MalignancyOncologyRelapsed Multiple MyelomaHematologyMyeloid Neoplasia +5
2011
910
Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trial
Sonia S. Hassan, Roberto Romero, D. Vidyadhari, +21
Ultrasound in Obstetrics and Gynecology
909
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios Α. Dimopoulos, Philippe Moreau, Antonio Palumbo, +28
Hematological MalignancyOncologyDexamethasone Versus BortezomibHematologyMyeloid Neoplasia +6
2015
834
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
Dae‐Hyun Yoo, Paweł Hrycaj, Pedro C. Miranda, +15
Annals of the Rheumatic Diseases
2013
650
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial
Pascal Vranckx, Marco Valgimigli, Lars Eckardt, +12
The Lancet
ThrombosisPercutaneous Coronary InterventionCardiovascular DiseaseEntrust-af PciPharmacology +11
2019
636
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
Won Park, Paweł Hrycaj, Volodymyr Kovalenko, +10
601
Randomized phase III study 306
Gregory L. Krauss, José M. Serratosa, Vicente Villanueva, +115
Neurology
2012
424
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
Sebastian Grosicki, Maryana Simonova, Ivan Špıčka, +55
Hematological MalignancyOnce-per-week SelinexorMedicineHematologyMyeloid Neoplasia +5
2020
310
Page 1